Targeting Ku-DNA Binding to Improve Specificity, Reduce Toxicity & Advance Next-Generation DDR Therapeutics
• Introducing Ku as the first responder to DNA double-strand breaks and a novel DDR target distinct from kinase inhibitors
• See how Nerx BioSciences are disrupting Ku-DNA interactions to block DNA-PK activity with greater specificity and reduced toxicity
• Demonstrating how this upstream approach could deliver safer and more effective DDR therapies compared to traditional kinase inhibition